Search company, investor...

Predict your next investment

Corporation
BUSINESS PRODUCTS & SERVICES | Consulting & Outsourcing / Research, Engineering & Technical
cmta.com

Partners & Customers

1

About CMTA

CMTA is a consulting engineering firm specializing in sustainable, high performance design for education and health care. On July 16th, 2021, CMTA was acquired by Therma. Terms of the transaction were not disclosed.

Headquarters Location

10411 Meeting Street

Prospect, Kentucky, 40059,

United States

502-326-3085

Are you an investor?
Submit your portfolio details now to be considered in our investor rankings.

Latest CMTA News

Leading the Way: The CMTA Invests More Than $200K in Cutting-Edge CMT1A Organoid Research

Feb 21, 2024

News Provided By Share This Article The CMTA's new $200K+ investment accelerates CMT1A organoid research, revolutionizing treatment evaluation for Charcot-Marie-Tooth disease (CMT) By investing in cutting-edge methodologies like organoid modeling, the CMTA is laying the groundwork for accelerating advancements across multiple types of CMT.” — Dr. Katherine Forsey, CMTA Chief Research Officer GLENOLDEN, PENNSYLVANIA, USA, February 21, 2024 / EINPresswire.com / -- The Charcot-Marie-Tooth Association (CMTA), the largest philanthropic funder of Charcot-Marie-Tooth disease (CMT) research aimed at bringing treatments and a cure to patients, announced today an investment of more than $200,000 in new funding to develop an innovative organoid model of CMT1A, the most common form of this disease. This cutting-edge approach will enable scientists to efficiently evaluate potential treatments that target defects in myelin, the protective sheath around peripheral nerves. Led by Professor Vincent Timmerman, Ph.D., the Peripheral Neuropathy Research Group at the University of Antwerp in Belgium is spearheading a project aimed at assessing CMT1A organoids to accelerate drug testing. Dr. Timmerman is a pioneer in the creation of these miniature organs from induced pluripotent stem cells (iPSCs). “As we recently developed human-derived miniature organ-like structures, here named organoids,” said Dr. Timmerman, “we highly appreciate the support of the CMTA which will allow us to characterize this system for evaluating CMT1A neuropathy. The availability of a three-dimensional structure will allow a qualitative and quantitative assessment of candidate therapies enhancing preclinical studies.” "As we embark on this pioneering project to develop organoid models for CMT1A, we're not just addressing a singular aspect of the disease; rather, we're contributing to a larger framework of research aimed at revolutionizing how we understand and treat CMT,” said Katherine Forsey, Ph.D., CMTA Chief Research Officer. “By investing in cutting-edge methodologies like organoid modeling, the CMTA is not only accelerating progress toward effective treatments for CMT1A but also laying the groundwork for advancements across multiple types of CMT. This strategic investment underscores our commitment to leveraging innovative approaches and collaborative partnerships to drive meaningful impact for CMT patients worldwide." About CMT Named after the three doctors who first described it in 1886: Charcot, Marie, and Tooth, CMT affects one in every 2,500 people—a rare disease subdivided into multiple subtypes, each with a lower prevalence. Due to the degradation of their nerves, people with CMT suffer lifelong progressive muscle weakness and atrophy of the arms and legs, and can affect other parts of the body. This leads to problems with balance, walking, hand use, and more. There currently is no treatment or cure for this debilitating disease. About the CMTA The CMTA is a community-led, community-driven 501(c)(3) nonprofit organization with a mission to support the development of new treatments for CMT, to improve the quality of life for people with CMT, and, ultimately, to find a cure. As the leading global philanthropic funder of CMT research, the CMTA unites the community with clinicians and industry experts to accelerate the advancement of treatments, with investments of more than $24 million since 2008. For more information, visit https://www.cmtausa.org Kenny Raymond

CMTA Acquisitions

5 Acquisitions

CMTA acquired 5 companies. Their latest acquisition was KLOK Group on January 23, 2023.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/23/2023

$99M

Merger

4

1/25/2022

Subscribe to see more

$99M

Subscribe to see more

10

2/11/2020

Subscribe to see more

$99M

Subscribe to see more

10

3/1/2019

Subscribe to see more

$99M

Subscribe to see more

10

2/24/2016

Subscribe to see more

$99M

Subscribe to see more

10

Date

1/23/2023

1/25/2022

2/11/2020

3/1/2019

2/24/2016

Investment Stage

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Total Funding

Note

Merger

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

CMTA Partners & Customers

1 Partners and customers

CMTA has 1 strategic partners and customers. CMTA recently partnered with Warren County Public Schools on July 7, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

7/13/2020

Partner

United States

Achieving the First ESCO-Funded Zero Energy Project.

The construction of a new elementary school was just one element of a district-wide energy savings partnership between WCPS and CMTA .

1

Date

7/13/2020

Type

Partner

Business Partner

Country

United States

News Snippet

Achieving the First ESCO-Funded Zero Energy Project.

The construction of a new elementary school was just one element of a district-wide energy savings partnership between WCPS and CMTA .

Sources

1

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.